C ytidine-5Ј-diphosphocholine (CDP-choline or citicoline) is an essential intermediate in the synthesis of phosphatidylcholine, a major brain phospholipid. Exogenous CDPcholine is hydrolyzed and absorbed as cytidine and choline, and CDP-choline is resynthesized by CTP-phosphocholine cytidylyltransferase, which is the rate-limiting enzyme in phosphatidylcholine synthesis. [1] [2] [3] [4] CDP-choline also serves as a choline donor in the biosynthesis of the neurotransmitter acetylcholine. CDP-choline has been studied in Ͼ11 000 volunteers and patients and has shown beneficial effects in cerebral ischemia, traumatic brain injury, and memory disorders. The tolerance of CDP-choline is excellent and side effects are rare, never severe, and consist mainly of digestive intolerance, gastrointestinal discomfort, and restlessness. [1] [2] [3] [4] The research on citicoline continues to explore new mechanisms of action and its neuroprotectant/neurorestorative potential. We focus on the results with citicoline communicated last year.
Basic Research
Lee et al 5 investigated whether citicoline can attenuate white matter lesions and cognitive decline caused by chronic hypoperfusion in the rat by conducting a histopathologic investigation and cognitive behavior test. Animals were divided into immediate and delayed treatment groups. Those in the immediate treatment group received a sham operation, citicoline (500 mg/kg per day), or phosphate-buffered saline treatment for 21 days after occluding the bilateral common carotid arteries. In the delayed treatment group, rats received either citicoline 500 mg/kg per day or phosphate-buffered saline for 21 days beginning on day 8 after the operation. Citicoline or phosphate-buffered saline was administered intraperitoneally. From the day 17 of administration, the rats were placed in an 8-arm radial maze to examine their cognitive abilities. In the immediate treatment group, cognitive functions were preserved in the citicoline-treated group, and white matter damage and TUNEL-positive cells differed significantly between the citicoline-treated and phosphatebuffered saline-treated animals. In the delayed treatment group, there was no decrease in white matter damage and TUNEL-positive cells, but cognitive improvement was evident for citicoline treatment relative to phosphate-buffered saline treatment. The authors concluded that citicoline can prevent white matter damage and aid cognitive improvement, even after a certain extent of disease progression.
During the last European Stroke Conference (Barcelona, May 2010), there were 2 new presentations on citicoline basic research. Giralt et al 6 used for the first time to our knowledge a systematic review and meta-analysis methodology to assess the evidence for a protective effect of citicoline in animal stroke models. Forty-two studies of citicoline treatment in animal models of cerebral ischemia were identified. Fifteen studies on focal ischemia were analyzed describing procedures involving 313 animals and reporting the effect of citicoline on infarct size (nϭ313) or functional outcome (nϭ104). The quality of the studies ranged from 0 to 10 based on good laboratory practice recommendations. Overall, citicoline reduced infarct volume by 28% (95% CI, 19 -38; PϽ0.001), and the reduction was greater in transient ischemia (30%; 95% CI, 15-45) than in permanent ischemia models (25%; 95% CI, 17-33). There was no improvement in neurological outcome (13%; 95% CI, 4 -30; Pϭ0.2). The quality of the studies was modest (scoreϭ5; interquartile range, 4 -8). However, when stratifying by quality scores (0 -4 [low-quality] vs 5-10 [high-quality]), studies with better quality showed the same effect of citicoline on infarct size reduction (30%; 95% CI, 25-34) than those with lowquality scores (29%; 95% CI, 25-33). Comparing doses, animals treated with higher doses (300 -500 mg/kg) had greater improvement (27%; 95% CI, 9 -46) than animals treated with lower doses (100 -300 mg/kg; 18%; 95% CI, 5-32; PϽ0.001). The authors concluded that this meta-anal-ysis provides further evidence of the beneficial effect of citicoline in reducing infarct volume, indicating doses of 300 to 500 mg/kg as optimal to translate into a candidate neuroprotective drug for human stroke.
It is known that the stimulation of endogenous trophic factors or exogenous administration of mesenchimal stem cells (MSC) can enhance neurological repair and recovery. In another communication, Gutiérrez et al 7 analyzed the therapeutic effects of citicoline, MSC, and their combination on repair and functional recovery after permanent middle cerebral artery occlusion. Sprague-Dawley male rats (Harland Ibérica SL, Barcelona; nϭ35) were distributed in 5 groups: 1, sham; 2, control; 3, citicoline (intraperitoneal, 500 mg/kg); 4, MSC (intravenous, 2ϫ10 6 cells); 5, combination (MSCϩciticoline). Treatment effect was evaluated by functional scales, infarct volume measured on MR, and tissue slices with hematoxylin and eosin staining, neuronal death by TUNEL staining, cellular proliferation by BdrUrd immunohistochemistry, vascular endothelial growth factor expression by immunofluorescence, and plasmatic levels of IL-6 and tumor necrosis factor-␣ by enzyme-linked immunosorbent assay. Rats were euthanized at 14 days. All treatment groups at 24 hours and 14 days showed significantly better neurological score than control groups, but there were no differences between them (Figure 1 ). No treatment reduced infarct volume, but citicoline and MSC decreased the TUNEL ϩ cells (PϽ0.05) and increased BrdUrd ϩ cells and vascular endothelial growth factor expression in peri-infarct zone compared to the control group. The authors concluded that citicoline and MSC administration show equal efficacy in neurological recovery, decrease of neuronal death, and increase of signatures of neurogenesis and angiogenesis.
It has been shown that increased iron stores are independently associated with poor outcome in patients with acute stroke. 8 In this way, Gregorio-Rocasolano et al 9 demonstrated that citicoline is able to protect neurons against iron toxicity. They incubated primary cultured neurons with iron 48 hours before a 90-minute period of oxygen glucose deprivation. Cell death was determined 15 minutes and 24 hours after returning to normoxia (reperfusion). Pretreatment with 20 and 50 mol/L iron increased early neuronal cell death compared to nontreated cultures. The net difference in the percentage of cell death between 15 minutes and 24 hour after reperfusion was maximal in controls and decreased in an iron concentration-dependent manner. The authors concluded that iron overload increases early cell death after reperfusion and decreases the percentage of cells alive than can be saved after returning to normoxia (Figure 2 ).
Clinical Research
Saver 10 published a formal study-level meta-analysis including 10 trials of citicoline in stroke, both ischemic and hemorrhagic. The aim of this meta-analysis was to analyze if citicoline confers a treatment benefit. Among the 2279 patients enrolled across all trials, assignment to citicoline compared to placebo was associated with a substantial reduction in the frequency of death or disability at long-term follow-up (57.0% vs 67.5%; OR, 0.64; 95% CI, 0.54 -0.77; PϽ0.001). The analysis confined to the 4 largest (nϾ100) ischemic stroke patient trials yielded a homogenous group of well-reported trials and obtained similar results. A safety analysis of all trials reporting mortality outcomes at the end of follow-up showed no adverse effect of citicoline: citicoline 179/1235 (14.5%) vs placebo 135/966 (14.0%; OR, 0.99; 95% CI, 0.77-1.21; Pϭ0.94).
Recently, a postmarketing surveillance study has been published. 11 The aim was to determine the efficacy and safety At 24 hours and 14 days, all treatment groups showed better functional evaluation score than control groups (PϽ0.05). There were no differences between treatment groups.
Figure 2.
Protective effects of citicoline on cultured neurons exposed to iron at different concentrations. Bars show the proportion of neurons alive after oxygen glucose deprivation (OGD) for 90 minutes and 15 minutes of reperfusion and show the proportion of the total neurons dead 24 hours after reperfusion. Note that neurons exposed to iron and treated with citicoline show resistance to early death after reperfusion.
of oral citicoline in 4191 Korean patients with acute ischemic stroke. Oral citicoline (500 -4000 mg/d) was administered within the first 24 hours from symptoms onset in 3736 patients (early group) and Ͼ24 hours after stroke onset in 455 patients (late group) for at least 6 weeks. All outcome measures, including a short version of the NIHSS, Barthel Index, and modified Rankin Scale, were improved after 6 weeks of therapy (PϽ0.05). Citicoline safety was excellent; only 37 side effects were observed in 31 patients (0.73%). The most frequent were headache (nϭ3), gastrointestinal symptoms (nϭ5), systemic bleeding (nϭ4), and strokerelated complications (nϭ8).
It has been demonstrated that an increase of circulating endothelial progenitor cells (EPC) after acute ischemic stroke is associated with good functional outcome, reduced infarct growth, and neurological improvement. 12 In this way, Sobrino et al 13 investigated if the administration of citicoline, started in the acute phase of stroke, could increase the EPC concentration in blood. Forty-eight patients with a first-ever nonlacunar ischemic stroke were prospectively included in the study within 12 hours of symptoms onset. Patients received treatment (nϭ26) or no treatment (nϭ22) with oral citicoline (2000 mg/d for 6 weeks). EPC colonies were quantified as early outgrowth colony-forming-unit endothelial cells (CFU-EC). The EPC increment during the first week was defined as the difference in the number of CFU-EC between day 7 and admission. CFU-EC were similar at baseline between patients treated and not treated with citicoline (7.7Ϯ6.1 vs 9.1Ϯ7.3 CFU-EC; Pϭ0.819). However, patients treated with citicoline and recombinant tissue-plasminogen activator had a higher EPC increase compared to patients treated only with citicoline or those not treated (35.4Ϯ15.9 vs 8.4Ϯ8.1 vs 0.9Ϯ10.2 CFU-EC; PϽ0.001). In a logistic regression model, citicoline treatment (OR, 17.6; 95% CI, 2.3-137.5; Pϭ0.006) and co-treatment with citicoline and recombinant tissue-plasminogen activator (OR, 108.5; 95% CI, 2.9 -1094.2; Pϭ0.001) were independently associated with an EPC increment Ն4 CFU-EC. The authors concluded that the administration of citicoline and the coadministration of citicoline and recombinant tissue plasminogen activator increase EPC concentration in acute ischemic stroke.
Focusing on the neuroreparative effects of citicoline, Ortega et al 14 presented the results of a clinical trial assessing safety and efficacy of citicoline on preservation of neurocognitive functions after stroke. The authors included 347 patients with a first-ever stroke in whom cognitive functions were evaluated by a complete neuropsychological battery 6 weeks (Ϯ3 days) and 6 months (Ϯ7days) after the event. All of them received citicoline (2 g/d) during 6 weeks and then were randomly assigned either to continue citicoline treatment (1 g/d) up to month 6 (nϭ172) or to stop citicoline therapy (nϭ175). Cognitive decline was assessed in each neurocognitive function using logistic regression models. The mean age of the patients was 67.2 and mean time of education was 5.7 years. Baseline characteristics were comparable between groups. Thirty patients died during the follow-up. Four patients had adverse events related to citicoline but continued with the treatment. At 6 months, patients not treated with citicoline showed significantly higher cognitive impairment in attention, executive functions (OR, 1.7; 95% CI, 1.09 -2.73; Pϭ0.019), and temporal orientation (OR, 1.73; 95% CI, 1.02-2.93; Pϭ0.042). The authors concluded that citicoline treatment during 6 months after a first ischemic stroke is safe and effective to improve neurocognitive impairment.
Two major clinical trials with citicoline are ongoing. The citicoline brain injury treatment trial (COBRIT), conducted in United States, is a randomized, double-blind, placebocontrolled, multicenter trial to analyze the effects of 90 days of citicoline (1000 mg twice per day) or placebo on functional outcome in patients with complicated mild, moderate, or severe traumatic brain injury. 15 In total, 1292 patients will be recruited over an estimated period of 32 months. The primary outcome consists of a set of scales that will be analyzed as a composite measure using a global test procedure at 90 days. The measures comprise the following core battery: the California Verbal Learning Test II; the Controlled Oral Word Association Test; Digit Span; Extended Glasgow Outcome Scale; the Processing Speed Index; Stroop Test part 1 and Stroop Test part 2; and Trail-Making Test parts A and B. Secondary outcomes include survival, toxicity, and rate of recovery. After an interim analysis, the sample size has been increased to close to 1500 patients, and the results are expected during 2011.
In Europe, we are developing the ICTUS trial. 16 This is a multicenter, randomized (under minimization), double-blind, placebo-controlled trial. The study will follow a sequential analysis (triangular model), 17 and the upper limit has been established in 2600 patients. This design has 80% power to establish a treatment effect of 1.26 (common OR). Primary end point will consist of a global score test combining 3 measures of success evaluated 12 weeks after treatment on the basis of intention-to-treat criteria: neurological (NIHSS score Յ1), disability (modified Rankin scale score Յ1), and activities of daily life (Barthel Index score Ն95), all averaged using a global test. ICTUS trial update was presented in the last European Stroke Conference; by May 3, 2010, 1497 patients had been included in 50 active centers in Spain, Clinical characteristics at baseline used for the minimization process of randomization.
